• ELUXA HM EMSI is an ongoing pivotal Phase

  2019-09-03

  

  ELUXA 1 (HM-EMSI-202) is an ongoing pivotal Phase II global clinical trial, designed to further investigate the efficacy and safety of Olmutinib in patients T790M-positive NSCLC with acquired resistance after first-line EGFR TKIs. Primary endpoint is ORR according to RECIST 1.1, while secondary endp

• TC-E 5003 clinical br Introduction The protein Epidermal Gro

  2019-09-03

  

  Introduction The protein Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) play important role in non small-cell lung carcinoma (NSCLC) and vital therapeutic progress withinin the treatment of this ailment has revamped the past ten years through the exploitation of this insight (Mok et a

• Although the phase I clinical trial of LMB was unsuccessful

  2019-09-02

  

  Although the phase I clinical trial of LMB was unsuccessful, the detailed review of this trial only mentions some malaise and anorexia as side effects, which are common for most effective chemotherapeutic drugs. These side effects may diminish if lower doses are administered. In view of the novel CR

• memantine hcl The structure of the HOIP RBR

  2019-09-02

  

  The structure of the HOIP RBR–LDD module bound to UbcH5~Ub reveals insights into an activated HOIP component [47]. Contacts between the E2~Ub and the non-cognate RBR module in the crystal suggest how a structure in which the active sites of the E2 and the E3 are in close proximity might look. In th

• thyroid hormone receptor br Materials and methods br Results

  2019-09-02

  

  Materials and methods Results Discussion Plg plays important roles in various physiological processes, such as fibrinolysis, proteolysis, cell migration, differentiation, tissue remodeling, and inflammation [6], [7], [8]. We herein found that Plg deficiency enhanced insulin secretion, and w

• For membrane protected SPE the choice of sorbent

  2019-09-02

  

  For membrane protected μ-SPE, the choice of sorbent is crucial because it determines the extraction efficiency. Up to now, many porous materials, such as carbon based sorbents [1,[3], [4], [5], [6]], ethylsilane or octadecylsilane modified silica (C2 or C18) [7,8], polymeric materials [[9], [10], [1

• br The estrogen receptors History

  2019-09-02

  

  The estrogen receptors: History and discovery In 1958, Elwood Jensen discovered the estrogen receptor, the first receptor ever encountered for any hormone, by showing that reproductive female tissues were able to uptake estrogen from the circulation by binding to proteins. He later demonstrated t

• br Introduction The cervix is a poorly studied component of

  2019-09-02

  

  Introduction The Cyanine 5-dUTP mass is a poorly studied component of the mare’s reproductive tract. It has anatomical and biological defense mechanisms involved in the delicate balance between immunological tolerance, sperm transport and biological defense. Anatomically, the cervix is composed

• Amyloid Beta-peptide (25-35) Considering these reports and w

  2019-09-02

  

  Considering these reports, and with the aim of further investigating the mechanism by which the cAMP-Epac/PKA pathway activates eNOS, we have performed imaging experiments evaluating the effect of drugs that increase cAMP or modify its signalling pathways (PKA or Epac activators and inhibitors) on b

• br Materials and methods br Results br Discussion

  2019-09-02

  

  Materials and methods Results Discussion Here we show expression of the EP1 receptor in the hippocampus of mice and the functional influence of the EP1 receptor on kainic RVX-208 induced seizures. Mice lacking a functional EP1 receptor gene displayed a lower tendency to enter status epilep

• br Conflict of interest br Acknowledgements This work was su

  2019-09-02

  

  Conflict of interest Acknowledgements This work was supported by the Basic Science Research Program through the National Research Foundation (NRF) funded by the Ministry of Science, ICT & Future Planning (2013R1A1A1076117) and also by the Priority Research Centers Program through the NRF funde

• Compared with qualitative analysis by Kalyankar et al less

  2019-09-02

  

  Compared with qualitative analysis by Kalyankar et al. (2013), less sequences were identified in iTRAQ-labelled analysis. It is not surprising with the finding that each of the identified peptide includes the sequence in every sampling point. Glu(51)-Tyr(52) of αs2-casein was observed to have been c

• br P Y receptor structure br Pharmacology Several subtype se

  2019-09-02

  

  P2Y receptor structure Pharmacology Several subtype selective compounds have been developed in recent years (Jacobson and Müller, 2016; Rafehi and Müller, 2018). These compounds are helpful tools for analyzing the roles of P2Y receptor subtypes in physiology and pathophysiology. The present ar

• In addition to its HEAT repeats CRM also possesses a

  2019-09-02

  

  In addition to its HEAT repeats, CRM1 also possesses a C-terminal extension (C-extension, residues 1032–1071), composed of a helix (C-helix) followed by a short stretch of residues (C-tail). In the absence of Ran, the C-extension adopts a conspicuous conformation that bridges across the ring-shaped

• Compound A and Compound B Fig

  2019-09-02

  

  Compound A and Compound B (Fig. 4) were found in our in vitro screening assays and have similar CRF1 receptor in vitro profiles (Table 1). When binding was investigated using [125I]-CRF in ex vivo assay, Compound A inhibited binding of [125I]-CRF both in the frontal cortex and the pituitary; however

16195 records 980/1080 page Previous Next First page 上5页 976977978979980 下5页 Last page